Healthcare Professionals

ACE Clinical Guidances (ACGs)

icon1
View Guidances

ACE CUES

icon1b

Find Out More

ACE Technology Guidances

icon2
View Guidances
Published on 08 Feb 2023
Last Updated on 08 Feb 2023
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended the following inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA) inhalers for inclusion on the MOH Standard Drug List (SDL) for treating asthma in view of acceptable clinical and cost-effectiveness:
  • Fluticasone furoate/vilanterol (Relvar Ellipta) 100/25 mcg (30 inhalations) and 200/25 mcg (30 inhalations) inhalation powder;
  • Budesonide/formoterol (DuoResp Spiromax) 160/4.5 mcg (120 inhalations) and 320/9 mcg (60 inhalations) inhalation powder.

The Committee has also recommended the following ICS/LABA inhalers for retention on the MOH SDL, in view of acceptable proposals from the companies:

  • Fluticasone propionate/salmeterol (Seretide Accuhaler) 100/50 mcg (60 inhalations), 250/50 mcg (60 inhalations), 500/50 mcg (60 inhalations) inhalation powder;
  • Fluticasone propionate/salmeterol (Seretide Accuhaler) 100/50 mcg (60 inhalations), 250/50 mcg (60 inhalations), 500/50 mcg (60 inhalations) inhalation powder;
  • Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mcg (120 inhalations) inhalation powder
  • Budesonide/formoterol (Symbicort Rapihaler) 80/2.25 mcg (120 inhalations), 160/4.5 mcg (120 inhalations) inhalation aerosol.

Of note, Symbicort Turbuhaler 80/4.5 mcg, 320/9 mcg and Symbicort Rapihaler 80/4.5 mcg will be delisted with effect from 1 August 2023 due to discontinuation by the company.

The subsidy class and subsidy implementation dates (if applicable) for all ICS/LABA inhalers are provided in the Annex.

 


Inhaled corticosteroids with long acting beta2 agonists for treating asthma (Published 8 Feb 2023)